BONESUPPORT Q2: Strong development, but more leg room for the share - Redeye

Redeye sees that BONESUPPORT is well-equipped to surpass its new 50% 2024e sales growth target, and we positively reconsider our US CERAMENT G open trauma sales rampup. Despite a lower-than-expected EBIT, the coming quarters should allow the company to demonstrate its excellent operating leverage more clearly. We up our fair value range somewhat.

Länk till analysen i sin helhet: https://www.redeye.se/research/1021427/bonesupport-q2-strong-development-but-more-leg-room-for-the-share?utm_source=finwire&utm_medium=RSS